Related Experiment Video
Updated: Jun 15, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
[Posterior reversible encephalopathy syndrome in autoimmune disorders]
I A Koltsov1,2, I A Shchukin1,2, M S Fidler1
1Pirogov Russian National Research Medical University, Moscow, Russia.
Posterior reversible encephalopathy syndrome (PRES) presents with varied neurological symptoms and characteristic brain imaging. While often linked to high blood pressure, PRES can also occur in non-hypertensive individuals due to autoimmune conditions or toxic exposures.
Area of Science:
- Neurology
- Radiology
- Pathophysiology
Background:
- Posterior reversible encephalopathy syndrome (PRES) is a neurological condition.
- It is defined by nonspecific neurological symptoms and characteristic posterior vasogenic edema on neuroimaging.
- PRES is typically associated with acute arterial hypertension but can occur in other contexts.
Purpose of the Study:
- To summarize the key features of Posterior Reversible Encephalopathy Syndrome (PRES).
- To discuss the varied clinical presentations and neuroimaging findings of PRES.
- To explore the underlying pathophysiological mechanisms of PRES.
Main Methods:
- Review of clinical and neuroimaging characteristics of PRES.
- Analysis of etiological factors including hypertension, autoimmune disorders, and toxic exposures.
- Discussion of the pathophysiological mechanisms involving cerebral blood flow autoregulation and endotheliopathy.
Main Results:
- PRES exhibits diverse neurological signs, both focal and non-focal.
- Neuroimaging predominantly shows vasogenic edema in the posterior brain regions.
- PRES can manifest in hypertensive patients, non-hypertensive individuals with autoimmune diseases, and those exposed to toxins.
Conclusions:
- PRES is a complex syndrome with multifactorial causes.
- Understanding the diverse triggers and mechanisms is crucial for diagnosis and management.
- Further research into the endotheliotropic effects may reveal new therapeutic targets.
More Related Videos
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019